Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut

Event · Earnings
Original reporting
Published Nov 17, 2026, 2:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PULM
Bullish
medium confidence
Mentioned
$PULM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PULMBullishMed
01

Why it matters

The 8-K provides fresh, tradable deal-status milestones (SEC effectiveness and stockholder approval) and updates on financial condition and the company’s strategy to out-license or monetize clinical assets while development is paused.

02

Market read

Traders may reprice Pulmatrix’s merger-close odds and near-term liquidity risk based on the newly disclosed SEC effectiveness, stockholder approval, and reduced cash balance.

03

What to watch

Cash fell materially from Dec. 31, 2025 to Sept. 30, 2026, and all clinical development is on hold, which could increase dilution or financing expectations even if the merger advances.

Relevance 7/10Novelty 6/10Timing: today’s EDGAR 8-K, with merger close targeted by end of year

Background

Pulmatrix is a Nasdaq-listed biopharma focused on inhaled therapeutics using its iSPERSE technology and has an announced merger agreement with privately held Eos SENOLYTIX.

Company-level read

Ticker impact

$PULMBullishMedium confidence
Context

Pulmatrix reports Q3 2026 results and says it has SEC effectiveness and stockholder approval for its merger with Eos SENOLYTIX, targeting year-end close.

Expected impact

Likely upward bias as investors price higher odds of year-end merger completion, partially offset by low cash and clinical development being on hold.

Evidence & confidence

The filing is a primary EDGAR 8-K with merger milestones (SEC effectiveness, stockholder approval) and updated financial position (cash down vs prior year-end) plus a stated plan to license/monetize assets while development is on hold.

Market effects

Biopharma deal-making and inhaled therapeutics licensing narratives may see incremental attention, but impact is company-specific.

Limited, as this is a small-cap US biotech corporate update.

Low; includes India Phase 3 approval context for a partner asset, but the primary tradable catalyst is the US-listed issuer’s merger progress.

Counterpoint

Year-end merger timing still depends on Nasdaq listing approval and a reverse stock split, so the update may not eliminate execution risk.

Key entities

  • Pulmatrix, Inc.

    Nasdaq-listed biopharmaceutical company filing the 8-K with Q3 2026 results and merger progress update.

  • Eos SENOLYTIX, Inc.

    Privately held biotechnology company that is the target in Pulmatrix’s proposed merger.

  • Cipla Technologies

    Partner developing PUR1900 in India, including approval to proceed to Phase 3.

  • MannKind Corporation

    Licensor/partner for iSPERSE technology in certain fields of use.

Related articles

$PULMMedAI 8/10

Eos reports early rat study data for aging drug candidate

Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.

$PULMMed

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.